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This work summarizes current knowledge and recommendations regarding sports activities
of patients with hypertrophic cardiomyopathy. Competitive sports, sports with high inten-
sity level and burst exertion are not recommended. Also performing sports in extremely
adverse environmental conditions as hot or cold weather, or high humidity is strongly
discouraged; dehydration represents a risk factor as well. Recreational sports are permitted,
particularly when individual risk factors and level of outﬂow tract obstruction are assessed
in an individual patient.
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. heTAlthough hypertrophic cardiomyopathy (HCM) is a disease,
which is known almost 60 years, change of opinions on the
condition has occurred many times in history, and sometimes
there has been 180-degree turn around. The most fundamental
change concerned the prognosis of HCM. Until recently, it has
been generally accepted that the prognosis of HCM is utterly
unfavorable, and patients are at any time in danger of sudden
cardiac death, which affects most of them with annual
mortality range from 2% to 4% in adults and 6% in children.
Majority of deaths have been supposed to be sudden [1–5].
Contemporary view is different. Prognosis of HCM seems to
be a guite good in low-risk patients with annual mortality not
exceeding 1% in last 40 years [6–8]. Only half of deaths have
been sudden, and remaining deaths have been caused by heart
failure or stroke [6,7]. Lower mortality in these patients cannot
be explained by the positive impact of treatment strategies
(except for implantable cardioverter-deﬁbrillator implanta-
tions in last years), but rather by more sensitive diagnostic* Tel.: +420 267162700.
http://dx.doi.org/10.1016/j.crvasa.2014.12.003
0010-8650/# 2014 Published by Elsevier Urban & Partner Sp. z o.o. on .algorithms enabling to identify mild (or even borderline) forms
of the disease, which has not been formerly detectable. Well
known risk factors are associated with risk of sudden death,
young people with early phenotype of HCM have also serious
prognosis [7]. Severe left ventricular outﬂow tract obstruction
(Vmax > 4 m/s) can deteriorate the prognosis of HCM, and is
more often associated with development of heart failure [8].
Current opinion of pregnancy in patients with HCM has
changed dramatically. Pregnancy in women with HCM has
been strongly discouraged in past [1,2], but nowadays, it is
considered safe and repeatable [9].
On the other hand, it would be incorrect to become
excessively optimistic because HCM takes its death toll,
particularly in young people. For example, in children aged
6–18 years, HCM is the main cause of sudden deaths together
with arrhythmogenic right ventricular cardiomyopathy [10].
Initially, patients with HCM have been strongly advised
against engaging in any sports activities [1–4]. Do our today'sbehalf of he Czech Society of Cardiology.T
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reﬂect current opinions on the HCM prognosis? We would
like to discuss this question in detail on following lines.
Even for non-professionals, it is evident while reading and
listening mass media and other sources that HCM can cause
death in the not negligible portion of young athletes. Recently,
particularly two tragic deaths have been made public: the
sudden death of a 19-year old Canadian hockey player of
Windsor Spitﬁres junior hockey team (Ontario Hockey League)
and also the death of another hockey player of same age –
former Jagr's teammate from Avangard Omsk. Both men died
from sudden death (the second one straight on the hockey
rink) after an unsuccessful resuscitation for cardiac arrest. In
both men, sudden death was caused by HCM. Naturally, such
events occur more often, but we don't know accurate numbers
of such cases.
Older works show unequivocally that HCM is the most
common cause of sudden death in young athletes. HCM
accounts for one third to one half of sudden death cases
[11–13]. Also, the last work published on the topic of sudden
death in young athletes clearly demonstrates [14] that HCM is
the predominant cause of this condition (Table 1). Forty seven
cases out of 182 cases of sudden death in young athletes
reported in 10 years had been conﬁrmed to be of cardiovascu-
lar cause. Out of them almost one half (21 students) died from
HCM. The most frequent sports presented in this report were
basketball (23 students) and soccer (16 students). Twenty nine
students died while engaged in competitive sports, and
14 students were engaged in recreational sports.
Of note, other work has dealt with sudden death in
marathon runners [15]. In total 10.9 million runners registered
between years 2000–2010, and 59 of them (aged 42  13 years,
51 men) experienced cardiac arrests. Vast majority of arrests
was caused by HCM plus coronary artery disease. The
strongest predictor of survival was except for early cardiopul-
monary resuscitation also other etiology than HCM, which
certainly suggested an important role of this disease in the
genesis of cardiac arrest resulting in sudden death in
marathon runners.
Thus, HCM is the most common cause of sudden deaths in
young people. The patients who can be very old, and have
almost no symptoms of the disease, and usually die from otherTable 1 – Sudden death in young athletes with confirmed
cardiovascular cause [14].
Cause Number
HCM 21
Coronary artery anomaly 8
CAD 5
Aortic dissection 3
ARVC 3
Dilated cardiomyopathy 2
Myocarditis 2
Long QT syndrome 1
Mitral valve prolapse 1
Kawasaki syndrome 1
ARVC, arrhythmogenic right ventricular cardiomyopathy; CAD,
coronary artery disease; HCM, hypertrophic cardiomyopathy.(mostly non-cardiac) causes, are on the other end of the age
spectrum of patients with HCM. Such ﬁndings have been
demonstrated by the data from Maron's database of 1297
patients with HCM [16] comprising 26 patients (2%) older than
90 years (the oldest patient was almost 97-years old) who were
mostly women (69%), which is common in similar cases. In
young patients with HCM, however, the situation is rather
different; prognosis of the disease is signiﬁcantly unfavorable
in this population. Nevertheless, the older patients are not
usually engaged in sports activities.
The view on sports activities in HCM has changed step by
step. Any physical activity has been strongly discouraged in
older works [1–4], but over the years, more detailed recom-
mendations have been created and published by American
College of Cardiology in years 1985, 2005, and 2008 [17–19]. In
2005, also the statement of European Society of Cardiology has
been released [20]. It is understandable that the detailed
guidelines could have not been created and based solely on
evidence-based medicine because the appropriate data cover-
ing all aspects of this topic are not available. Thus, the
recommendations have been based mostly on consensus of
experts.
So what about sports activities and HCM? Competitive
sports with high level of physical intensity represent high risk
[8–21]. Also sports with burst exertion (running and sports
associated with it as soccer, basketball and other sports)
should be avoided. Aerobic (not isometric) exertion is
preferred. Sports activities performed in extremely adverse
environmental conditions (hot or cold weather, high humidity)
are not advised. It is important to replenish ﬂuids (dehydration
presents very high risk in patients with HCM, and this is true
not only during physical activity). The activities as using sauna
or whirlpool are not suitable [22,23]. In recreational sports
activities, recommendations should be assessed on an
individual basis with respect to his/her risk factors, particu-
larly ventricular arrhythmias [18] and left ventricular outﬂow
tract obstruction [21]. On the other hand, it is important to
emphasize that even patients with HCM without all ‘‘classical’’
risk factors are not spared of sudden death risk, especially
while engaged in competitive sports with high level of physical
intensity [19,24]. Undoubtedly, it is related to the fact that not
all risk factors are known currently, and we are not able to
identify reliably all endangered patients. One of such risk
factor, in which we are not able to describe the level of risk and
danger for their carriers, is the presence of extensive ﬁbrosis,
especially affecting papillary muscles, which could impact an
arrhythmogenic substrate [25].
Table 2 presents the categorization of sports with regard to
the intensity level. According to the guidelines of American
professional societies [21], all sports are assigned grades
indicating eligibility. The graded scale starts with sports
generally not advised in HCM (0–1), and ends with sports
admissible and probably permitted in HCM (4–5). There is
continuous spectrum between those two poles (2–3). Table 2
shows that the sports with high intensity level usually cannot
be advised, and on the contrary, the sports with low intensity
level can be recommended except for diving.
The conference in Bethesda in 2008 [19] was also concerned
with the problem of patients with the positive cardiomyopathy
genotype (not only HCM, but also dilated cardiomyopathy,
Table 2 – Recommendations for the acceptability of
recreational (noncompetitive) sports activities and
exercise in patients with HCM [21].
Eligibility scale
for HCM
Intensity high
 Basketball 0
 Body building 1
 Gymnastics 2
 Ice hockey 0
 Racquetball/squash 0
 Rock climbing 1
 Running (sprinting) 0
 Skiing (downhill) 2
 Skiing (cross-country) 2
 Soccer 0
 Tennis (singles) 0
 Windsurﬁng 1
Intensity moderate
 Baseball/softball 2
 Biking 4
 Hiking 3
 Motorcycling 3
 Jogging 3
 Sailing 3
 Surﬁng 2
 Swimming (laps) 5
 Tennis (doubles) 4
 Treadmill/stationary bicycle 5
 Weightlifting (free weights) 1
Intensity low
 Bowling 5
 Brisk walking 5
 Golf 5
 Horseback riding 3
 Scuba diving 0
 Skating 5
 Snorkeling 5
Recreational sports are graded on a relative scale for eligibility with
0 to 1 indicating generally not advised or strongly discouraged
sports and 4 to 5 indicating probably permitted sports.
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called channelopathies included among cardiomyopathies in
US) and without the phenotype of the disease. According to the
American guidelines, these patients should not be discouraged
from sports activities. Recommendations of the European
Society of Cardiology from year 2005 are stricter, and they
recommend only recreational sports in such cases. This
recommendation is justiﬁed by the assumption that regular
exercise and competitive sports activities can trigger cell
mechanisms leading to the development of HCM (myocardial
hypertrophy) and arrhythmias. This contradiction is pre-
sented also in more recent works [26].
It is very important to identify all patients with HCM who
are planning to start sports activities. All athletes with
abnormal ECG including high voltage QRS complex, inverted
T waves, or pathological Q waves have to be carefully
examined. The echocardiographic examination is crucial,
but also the detailed family screening and 24 hours ECG
monitoring are important [20]. If these tests are negative, these
individuals could exercise without restrictions [20].Naturally, it is of note that HCM and sports are also associated
in the different level than described above. Vigorous systematic
training can lead to myocardial hypertrophy and increase in
myocardial mass [27]. The clinical picture of this condition more
or less resembles HCM. Particularly in borderline forms of
myocardial hypertrophy, both conditions could be confused. It is
clear that distinction between them is crucial since the ﬁnding of
hypertrophy is pathological in HCM and physiological in the
latter case. However, the differentiation between those two
conditions is beyond the scope of this article, and we refer to the
other texts for detailed information [22,27,28].
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